Trial Profile
A 1 year follow-up study to the G304 study to demonstrate the efficacy of the Grass MATA MPL (0.5 mL)
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 09 Jan 2015
Price :
$35
*
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary) ; Monophosphoryl lipid A
- Indications Grass pollen hypersensitivity
- Focus Therapeutic Use
- Sponsors Allergy Therapeutics
- 09 Jan 2015 New trial record